CX3CL1 and atherosclerosis: Pharmacological inhibition of the chemokine receptor, CX3CR1 has furthermore been described to inhibit leukocyte recruitment and to reduce atherosclerosis [16], indicating an important role of CX3CL1 in the pathogenesis of atherosclerosis.